Company intelligence / Profile preview

DeCell Technologies

Nova Scotia, Canadadecelltechnologies.com ↗

Ownership: Private
Development stage: Other

Overview

DeCell Technologies has developed a patented process to decellularize donated human tissue, removing cellular components while preserving the structural protein matrix. This results in a sterile biological scaffold that promotes tissue regeneration and reduces risk of rejection when implanted. The company’s products are used in wound healing and surgical reconstruction[1].

Therapeutic areas: DermatologyOther
Modalities: Biologic scaffold (processed human tissue)Device (biological implant)
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on DeCell Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DeCell Technologies.

Explore the full profile